Trial Profile
Efficacy of Atomoxetine in the Neuropsychological Tests Among Children With ADHD [attention-deficit hyperactivity disorder]
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2021
Price :
$35
*
At a glance
- Drugs Atomoxetine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- 06 May 2021 Status changed from active, no longer recruiting to completed.
- 18 Oct 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 02 Oct 2007 New trial record.